“Repeat dosing of AB-729 results in modest reductions in hepatitis B core-related antigen and hepatitis B e antigen,” the company said.
“Repeat dosing of AB-729 was safe and well tolerated.”
Further, “These data support the continued evaluation of AB-729 as the cornerstone of combination treatment to achieve functional cure of chronic Hepatitis B virus.”
Arbutus recently traded at $3.89, up 15%. The shares of the Warminster, Pa., company had slipped 7% in the six months through Friday.
In other health news, Pieris Pharmaceuticals (PIRS) - Get Pieris Pharmaceuticals, Inc. Report said on Friday that it received a grant from Bavaria to develop a drug to treat lung scarring suffered by long-term COVID victims.
The grant totals 14.2 million euro ($17 million) from the Bavarian Ministry of Economic Affairs. The inhaled drug is PRS-220. Clinical development of the program is expected to begin next year, the Boston company said.
That speeds the Food and Drug Administration’s consideration of the drug for marketing clearance. Lilly said it intends to submit a biologics-license application for donanemab later this year under the accelerated approval process.
Cowen analyst Steve Scala on Thursday affirmed an outperform rating for the company.
Analysts had upgraded Biogen after the FDA decision on Aduhelm, though the approval sparked criticism from some experts.